PHARMA MARKET LIVE | Antimicrobial resistance (AMR) is undoubtedly one of the greatest public health challenges of our time. Some progress is being made through organizations like CARB-X. But resistance levels continue to rise, people are dying, and now alarm bells are sounding for the future of live-saving treatments like chemotherapy for cancer. Even as the need for new diagnostics and antibiotics grows, we know that the markets for these products is in dire straits. In this opinion piece, Daniel Berman, Head of Global Health at Nesta Challenges, writes that we need an urgent change of direction in how we respond to AMR; it must be tackled on multiple fronts. That’s why a new funding mechanism is needed, one that will be initiated and backed by multiple players, including decision-makers and influencers in pharma and healthcare who know the scale of the challenges we face. We already have effective mechanisms that fund access to vaccines, TB, HIV and malaria. Why not an international AMR Fund to support uptake of products to tackle AMR too?